

Paolo Peterlongo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/933957/publications.pdf>

Version: 2024-02-01

189
papers

17,248
citations

22548

61
h-index

20023

121
g-index

205
all docs

205
docs citations

205
times ranked

20974
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19
2	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in <i>BRCA1</i> and <i>BRCA2</i> compared with those harboring protein truncating variants. <i>Genetics in Medicine</i> , 2022, 24, 119-129.	1.1	10
3	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	2.0	6
4	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
5	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. <i>JAMA Oncology</i> , 2022, 8, e216744.	3.4	51
6	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. <i>Genome Medicine</i> , 2022, 14, 51.	3.6	19
7	<i>CYP3A7*1C</i> allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	2.9	5
8	A case-only study to identify genetic modifiers of breast cancer risk for <i>BRCA1/BRCA2</i> mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	5.8	19
9	Breast Cancer Risk Genes Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	13.9	532
10	Detecting Variants in the <i>NBN</i> Gene While Testing for Hereditary Breast Cancer: What to Do Next?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5832.	1.8	6
11	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. <i>Human Genetics and Genomics Advances</i> , 2021, 2, 100042.	1.0	6
12	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
13	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	2.6	6
14	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	2.2	7
15	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	2.9	9
16	Protein truncating variants in <i>FANCM</i> and risk for ER-negative/triple negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 130.	2.3	6
17	Analysis of Italian <i>BRCA1/2</i> Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy. <i>Cancers</i> , 2021, 13, 532.	1.7	8
18	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
20	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
21	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020, 38, 674-685.	0.8	270
22	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
23	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. <i>JCO Precision Oncology</i> , 2020, 4, 916-925.	1.5	9
24	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
25	Germline <i>HOXB13</i> mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	1.6	2
26	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
27	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	5.8	30
28	The Spectrum of <i>FANCM</i> Protein Truncating Variants in European Breast Cancer Cases. <i>Cancers</i> , 2020, 12, 292.	1.7	11
29	Homologous recombination DNA repair defects in <i>PALB2</i> -associated breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, 23.	2.3	39
30	The <i>FANCM</i> :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	2.3	28
31	Two truncating variants in <i>FANCC</i> and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
32	Editorial: Accomplishments, Collaborative Projects and Future Initiatives in Breast Cancer Genetic Predisposition. <i>Frontiers in Oncology</i> , 2019, 9, 841.	1.3	0
33	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries. <i>Human Mutation</i> , 2019, 40, e1-e23.	1.1	34
34	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
35	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
36	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	2.9	52

#	ARTICLE	IF	CITATIONS
37	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	2.6	711
38	Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. <i>International Journal of Cancer</i> , 2019, 145, 390-400.	2.3	40
39	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
40	Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. <i>Endocrine Connections</i> , 2019, 8, 1224-1229.	0.8	6
41	The <i>BRCA2</i> c.68-7T>A variant is not pathogenic: A model for clinical calibration of spliceogenicity. <i>Human Mutation</i> , 2018, 39, 729-741.	1.1	19
42	Decapping protein EDC4 regulates DNA repair and phenocopies <i>BRCA1</i> . <i>Nature Communications</i> , 2018, 9, 967.	5.8	33
43	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
44	A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. <i>Breast</i> , 2018, 38, 92-97.	0.9	23
45	Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. <i>Genetics in Medicine</i> , 2018, 20, 452-457.	1.1	59
46	Proffered Papers and Posters Presented at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer – BrCA: From the Personal to the Population. <i>Current Oncology</i> , 2018, 25, 224-262.	0.9	2
47	Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. <i>Frontiers in Oncology</i> , 2018, 8, 583.	1.3	25
48	Two Missense Variants Detected in Breast Cancer Probands Preventing <i>BRCA2</i> - <i>PALB2</i> Protein Interaction. <i>Frontiers in Oncology</i> , 2018, 8, 480.	1.3	11
49	<i>BRCA1</i> and <i>BRCA2</i> 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. <i>Human Mutation</i> , 2018, 39, 2025-2039.	1.1	15
50	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
51	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	9.4	184
52	Abstract 1236: Insight into genetic susceptibility to BRCA-negative male breast cancer by multigene panel testing: Results from a multicenter study in Italy. , 2018, , .		1
53	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2789-2799.	0.4	75
54	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. <i>Npj Breast Cancer</i> , 2017, 3, 22.	2.3	108

#	ARTICLE	IF	CITATIONS
55	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
56	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
57	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
58	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
59	Whole-exome sequencing and targeted gene sequencing provide insights into the role of <i>PALB2</i> as a male breast cancer susceptibility gene. <i>Cancer</i> , 2017, 123, 210-218.	2.0	31
60	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	242
61	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	0.9	45
62	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. <i>Breast Cancer Research</i> , 2017, 19, 119.	2.2	43
63	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	0.8	152
64	Abstract P2-03-01: Mutational landscape of breast cancers from <i>PALB2</i> germline mutation carriers. , 2017, , .		0
65	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. <i>PLoS Medicine</i> , 2016, 13, e1002105.	3.9	118
66	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	1.1	10
67	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 1303-1317.	2.3	51
68	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
69	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
70	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016, 18, 22.	2.2	43
71	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016, 27, 679-693.	0.8	21
72	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88

#	ARTICLE	IF	CITATIONS
73	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. <i>Human Molecular Genetics</i> , 2016, 25, 3863-3876.	1.4	33
74	Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 121-129.	1.1	11
75	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
76	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
77	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
78	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). <i>Scientific Reports</i> , 2016, 6, 32512.	1.6	19
79	The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk. <i>Breast Cancer Research</i> , 2016, 18, 111.	2.2	11
80	Personalized testing based on polygenic risk score is promising for more efficient population-based screening programs for common oncological diseases. <i>Annals of Oncology</i> , 2016, 27, 369-370.	0.6	5
81	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. <i>Journal of Medical Genetics</i> , 2016, 53, 298-309.	1.5	94
82	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
83	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. <i>Human Genetics</i> , 2016, 135, 137-154.	1.8	8
84	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	3.0	77
85	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
86	RAD51B in Familial Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0153788.	1.1	26
87	Abstract 134: Mutational landscape of breast cancers from PALB2 germline mutation carriers. , 2016, , .		0
88	Abstract 1859: Bioinformatic and experimental evaluation of regulatory variants in breast cancer susceptibility genes. , 2016, , .		0
89	Constitutional de novo deletion of the <i>FBXW7</i> gene in a patient with focal segmental glomerulosclerosis and multiple primitive tumors. <i>Scientific Reports</i> , 2015, 5, 15454.	1.6	10
90	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26

#	ARTICLE	IF	CITATIONS
91	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	2.2	26
92	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 758-762.	0.2	0
93	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34
94	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	428
95	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015, 24, 2966-2984.	1.4	40
96	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	2.6	76
97	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. <i>Carcinogenesis</i> , 2015, 36, 256-271.	1.3	14
98	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
99	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	9.4	513
100	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. <i>European Journal of Cancer</i> , 2015, 51, 2289-2295.	1.3	25
101	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	1.4	91
102	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015, 97, 22-34.	2.6	37
103	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	56
104	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> , 2015, 47, 1294-1303.	9.4	357
105	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	3.0	99
106	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1680-1691.	1.1	24
107	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	1.4	38
108	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22

#	ARTICLE	IF	CITATIONS
109	Association between CASP8 652 6N Del Polymorphism (rs3834129) and Colorectal Cancer Risk: Results from a Multi-Centric Study. PLoS ONE, 2014, 9, e85538.	1.1	8
110	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	1.1	49
111	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	1.5	39
112	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
113	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	1.4	53
114	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	2.2	97
115	Breast-Cancer Risk in Families With Mutations in PALB2. Obstetrical and Gynecological Survey, 2014, 69, 659-660.	0.2	1
116	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
117	PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. Genetics in Medicine, 2014, 16, 688-694.	1.1	25
118	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	1.4	32
119	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97.	13.7	548
120	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	13.9	745
121	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	5.8	105
122	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	1.4	12
123	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	2.2	14
124	The MLH1 c.1852_1853delinsGC (p.K618A) Variant in Colorectal Cancer: Genetic Association Study in 18,723 Individuals. PLoS ONE, 2014, 9, e95022.	1.1	7
125	Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). Oncotarget, 2014, 5, 8223-8234.	0.8	22
126	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Research, 2013, 15, 402.	2.2	36

#	ARTICLE	IF	CITATIONS
127	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060.	2.6	98
128	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
129	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503.	2.6	201
130	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	9.4	374
131	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	9.4	960
132	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003173.	1.5	105
133	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
134	BMP2 / BMP4 colorectal cancer susceptibility loci in northern and southern European populations. <i>Carcinogenesis</i> , 2013, 34, 314-318.	1.3	14
135	Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles. <i>PLoS ONE</i> , 2013, 8, e55681.	1.1	95
136	Meta-Analysis of Mismatch Repair Polymorphisms within the Cogent Consortium for Colorectal Cancer Susceptibility. <i>PLoS ONE</i> , 2013, 8, e72091.	1.1	19
137	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	1.1	23
138	19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus. <i>Cancer Research</i> , 2012, 72, 1795-1803.	0.4	100
139	Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 645-657.	1.1	47
140	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939.	1.4	80
141	Genome-wide association analysis identifies three new breast cancer susceptibility loci. <i>Nature Genetics</i> , 2012, 44, 312-318.	9.4	256
142	Rare variants in XRCC2 as breast cancer susceptibility alleles: Table 1. <i>Journal of Medical Genetics</i> , 2012, 49, 618-620.	1.5	49
143	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1783-1791.	1.1	17
144	Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. <i>Familial Cancer</i> , 2012, 11, 483-491.	0.9	29

#	ARTICLE	IF	CITATIONS
145	Sequencing Analysis of SLX4/FANCP Gene in Italian Familial Breast Cancer Cases. PLoS ONE, 2012, 7, e31038.	1.1	10
146	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	1.1	35
147	Identification of fifteen novel germline variants in the 3' UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Human Mutation, 2012, 33, 1665-1675.	1.1	49
148	Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Research and Treatment, 2012, 134, 411-418.	1.1	73
149	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 132, 1119-1126.	1.1	8
150	Prospective study of breast tomosynthesis as a triage to assessment in screening. Breast Cancer Research and Treatment, 2012, 133, 267-271.	1.1	73
151	The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians. Breast Cancer Research and Treatment, 2012, 133, 805-807.	1.1	28
152	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
153	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
154	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
155	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	1.1	27
156	Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40.	2.2	23
157	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
158	The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2011, 125, 855-860.	1.1	11
159	No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women. Breast Cancer Research and Treatment, 2011, 126, 235-239.	1.1	16
160	PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. Breast Cancer Research and Treatment, 2011, 126, 825-828.	1.1	37
161	Evidence for a link between TNFRSF11A and risk of breast cancer. Breast Cancer Research and Treatment, 2011, 129, 947-954.	1.1	12
162	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	1.8	18

#	ARTICLE	IF	CITATIONS
163	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	1.4	68
164	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 4693-4706.	1.4	71
165	The rs12975333 variant in the miR-125a and breast cancer risk in Germany, Italy, Australia and Spain. <i>Journal of Medical Genetics</i> , 2011, 48, 703-704.	1.5	13
166	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 4732-4747.	1.4	32
167	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 105-116.	3.0	40
168	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. <i>PLoS Biology</i> , 2011, 9, e1001199.	2.6	91
169	Evaluation of SNPs in <i>miR-146a</i> , <i>miR196a2</i> and <i>miR-499</i> as low-penetrance alleles in German and Italian familial breast cancer cases. <i>Human Mutation</i> , 2010, 31, E1052-E1057.	1.1	147
170	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	9.4	309
171	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. <i>Cancer Research</i> , 2010, 70, 9742-9754.	0.4	169
172	A BRCA1 promoter variant (rs11655505) and breast cancer risk. <i>Journal of Medical Genetics</i> , 2010, 47, 268-270.	1.5	6
173	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. <i>PLoS Genetics</i> , 2010, 6, e1001183.	1.5	85
174	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009, 18, 4442-4456.	1.4	99
175	SNPs in ultraconserved elements and familial breast cancer risk. <i>Carcinogenesis</i> , 2009, 30, 544-545.	1.3	23
176	Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 607-608.	1.1	20
177	Toll-Like Receptor 4 Polymorphisms and Risk of Gram-Negative Bacteremia after Allogeneic Stem Cell Transplantation. A Prospective Pilot Study. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1130-1133.	2.0	17
178	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>American Journal of Human Genetics</i> , 2008, 82, 937-948.	2.6	257
179	The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. <i>Cancer Detection and Prevention</i> , 2008, 32, 140-143.	2.1	20
180	Increased frequency of disease-causing MYH mutations in colon cancer families. <i>Carcinogenesis</i> , 2006, 27, 2243-2249.	1.3	44

#	ARTICLE	IF	CITATIONS
181	TLR1 and TLR6 Polymorphisms Are Associated with Susceptibility to Invasive Aspergillosis after Allogeneic Stem Cell Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2005, 1062, 95-103.	1.8	186
182	Germline mutations of AXIN2 are not associated with nonsyndromic colorectal cancer. <i>Human Mutation</i> , 2005, 25, 498-500.	1.1	14
183	Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH. <i>International Journal of Cancer</i> , 2005, 114, 505-507.	2.3	56
184	TGFBR1*6A May Contribute to Hereditary Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3074-3078.	0.8	45
185	TGFBR1*6A and Cancer: A Meta-Analysis of 12 Case-Control Studies. <i>Journal of Clinical Oncology</i> , 2004, 22, 756-758.	0.8	85
186	Localization of Cancer Susceptibility Genes by Genome-wide Single-Nucleotide Polymorphism Linkage-Disequilibrium Mapping. <i>Cancer Research</i> , 2004, 64, 8116-8125.	0.4	12
187	MSH6 germline mutations are rare in colorectal cancer families. <i>International Journal of Cancer</i> , 2003, 107, 571-579.	2.3	53
188	Beneficial Effect of Fluoxetine in a Case of Sporadic Hyperekplexia. <i>Clinical Neuropharmacology</i> , 2000, 23, 161-163.	0.2	15
189	C-kit mutations in core binding factor leukemias. <i>Blood</i> , 2000, 95, 726-728.	0.6	271